| Number: 201107017 |
Principal Investigator: Tan, Benjamin |
| Title: A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin with Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients with Peritoneal Carcinomatosis from Appendiceal or Colorectal Cancer |
| Description: The main purpose of this research is to evaluate an intraperitoneal treatment for cancer following a surgical attempt to remove as much or all of the cancer as possible. The goals of this study are to determine the safety and side effects of this treatment, and to learn the maximum tolerated dose (...MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU N1048 |
Principal Investigator: Tan, Benjamin |
| Title: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (N1048) |
| Description: This trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery.
...MORE |
| ___________________________________________________________________________________________________ |
| Number: ACOSOG Z6051 |
Principal Investigator: Mutch, Matthew |
| Title: A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201202001 |
Principal Investigator: Zuckerman, Darryl |
| Title: A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy |
| Description: The purpose of this research study is to examine whether adding treatment with TheraSphere early in the current standard for second-line chemotherapy treatment of metastatic colorectal cancer is better
than the current treatment alone. Better means slowing or stopping the growth of liver tumors
...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201011820 |
Principal Investigator: Tan, Benjamin |
| Title: Protocol I4T-MC-JVBB (also known as IMCL CP12 0920) A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine |
| Description: The purpose of this research study is to see how safe an investigational drug called ramucirumab is and to see how well it helps people with colon cancer.
The primary purpose of this study is to help answer the following research questions:
Can ramucirumab help patients with colon cancer l...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201013045 |
Principal Investigator: Mutch, Matthew |
| Title: Molecular Markers to Predict the Behavior of Adenocarcinoma of the Rectum |
| ___________________________________________________________________________________________________ |
| Number: 201302001 |
Principal Investigator: Dharmarajan, Sekhar |
| Title: Colorectal Cancer in FAP Patients |
| ___________________________________________________________________________________________________ |
| Number: 201201119 |
Principal Investigator: Dharmarajan, Sekhar |
| Title: The Influence of an FAP Disease Registry on Outcomes in Ileorectal Anastomosis (IRA) and Ileal Pouch Anal Anastomosis (IPAA) |
| ___________________________________________________________________________________________________ |
| Number: 201107368 |
Principal Investigator: Nalbantoglu, ILKe |
| Title: LFAB and Colorectal Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201105072 |
Principal Investigator: Azar, Riad |
| Title: Advanced Colorectal Neoplasia In Patients Under 50 Years: Risk Factors and Outcomes |
| ___________________________________________________________________________________________________ |
| Number: 201212057 |
Principal Investigator: Wise, Paul |
| Title: Cancer risks and mutation spectrum of mismatch repair gene mutations in African American families with Lynch
syndrome |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |